Impaired fasting glucose is associated with increased regional cerebral amyloid

Neurobiology of Aging

Volumn 44, Issue , 2016, Pages 138-142

  Morris, Jill K ^a   Vidoni, Eric D ^a   Wilkins, Heather M ^a   Archer, Ashley E ^a   Burns, Nicole C ^a   Karcher, Rainer T ^a   Graves, Rasinio S ^a   Swerdlow, Russell H ^a   Thyfault, John P ^a   Burns, Jeffrey M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Apolipoprotein E; Dementia; Impaired fasting glucose; Insulin; Metabolism

Indexed keywords

APOLIPOPROTEIN E4; FLORBETAPIR F 18; GLUCOSE; AMYLOID; GLUCOSE BLOOD LEVEL;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEFAULT MODE NETWORK; FEMALE; FRONTAL CORTEX; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; RISK FACTOR; BLOOD; BRAIN; DIET RESTRICTION; GENETICS; HETEROZYGOTE; METABOLISM; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; APOLIPOPROTEIN E4; BLOOD GLUCOSE; BRAIN; FASTING; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; RISK; RISK FACTORS;

EID: 84971441734     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.04.017     Document Type: Article

References (38)

1. Alafuzoff I., Aho L., Helisalmi S., Mannermaa A., Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol. Appl. Neurobiol. 2009, 35:60-68.
2. Arvanitakis Z., Schneider J.A., Wilson R.S., Li Y., Arnold S.E., Wang Z., Bennett D.A. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006, 67:1960-1965.
3. Bailly M., Ribeiro M.J., Vercouillie J., Hommet C., Gissot V., Camus V., Guilloteau D. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease. Clin. Nucl. Med. 2015, 40:e111-e116.
4. Burns C.M., Chen K., Kaszniak A.W., Lee W., Alexander G.E., Bandy D., Fleisher A.S., Caselli R.J., Reiman E.M. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 2013, 80:1557-1564.
5. Cavanna A.E., Trimble M.R. The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006, 129:564-583.
6. Chao A.C., Lee T.C., Juo S.H., Yang D.I. Hyperglycemia increases the production of amyloid beta-peptide leading to decreased endothelial tight junction. CNS Neurosci. Ther. 2016, 22:291-297.
7. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y.D., Ma T., Thompson R.C., Zhao Y., Smith L., Gasparini L., Luo Z., Xu H., Liao F.F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. U S A 2009, 106:3907-3912.
8. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., Williams D.E., Gregg E.W., Bainbridge K.E., Saydah S.H., Geiss L.S. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes care 2009, 32:287-294.
9. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
10. Gusnard D.A., Raichle M.E., Raichle M.E. Searching for a baseline: functional imaging and the resting human brain. Nat. Rev. Neurosci. 2001, 2:685-694.
11. Hedden T., Van Dijk K.R., Becker J.A., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009, 29:12686-12694.
12. Hettich M.M., Matthes F., Ryan D.P., Griesche N., Schroder S., Dorn S., Kraubeta S., Ehninger D. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex. PLoS One 2014, 9:e102420.
13. Ishibashi K., Kawasaki K., Ishiwata K., Ishii K. Reduced uptake of (18)F-FDG and (15)O-H2O in Alzheimer's disease-related regions after glucose loading. J. Cereb. Blood Flow Metab. 2015, 35:1380-1385.
14. Ishibashi K., Onishi A., Fujiwara Y., Ishiwata K., Ishii K. Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. J. Nucl. Med. 2015, 56:229-233.
15. Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R., Visser P.J., Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I.S., Arnold S.E., Baldeiras I., Barthel H., van Berckel B.N., Bibeau K., Blennow K., Brooks D.J., van Buchem M.A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A.D., Drzezga A., Engelborghs S., Fagan A.M., Fladby T., Fleisher A.S., van der Flier W.M., Ford L., Forster S., Fortea J., Foskett N., Frederiksen K.S., Freund-Levi Y., Frisoni G.B., Froelich L., Gabryelewicz T., Gill K.D., Gkatzima O., Gomez-Tortosa E., Gordon M.F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W.J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W.E., Kohler S., Koglin N., Kornhuber J., Kramberger M.G., Van Laere K., Landau S.M., Lee D.Y., de Leon M., Lisetti V., Lleo A., Madsen K., Maier W., Marcusson J., Mattsson N., de Mendonca A., Meulenbroek O., Meyer P.T., Mintun M.A., Mok V., Molinuevo J.L., Mollergard H.M., Morris J.C., Mroczko B., Van der Mussele S., Na D.L., Newberg A., Nordberg A., Nordlund A., Novak G.P., Paraskevas G.P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G.D., Ramakers I.H., Rami L., Resende de Oliveira C., Rinne J.O., Rodrigue K.M., Rodriguez-Rodriguez E., Roe C.M., Rot U., Rowe C.C., Ruther E., Sabri O., Sanchez-Juan P., Santana I., Sarazin M., Schroder J., Schutte C., Seo S.W., Soetewey F., Soininen H., Spiru L., Struyfs H., Teunissen C.E., Tsolaki M., Vandenberghe R., Verbeek M.M., Villemagne V.L., Vos S.J., van Waalwijk van Doorn L.J., Waldemar G., Wallin A., Wallin A.K., Wiltfang J., Wolk D.A., Zboch M., Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015, 313:1924-1938. Amyloid Biomarker Study Group.
16. Kawasaki K., Ishii K., Saito Y., Oda K., Kimura Y., Ishiwata K. Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann. Nucl. Med. 2008, 22:191-200.
17. Kong J.J., Zhang D.D., Li P., Wei C.Y., Yu H.J., Zhang H., Zhang W., Wang Y.F., Cao Y.P. Nicorandil inhibits oxidative stress and amyloid-beta precursor protein processing in SH-SY5Y cells overexpressing APPsw. Int. J. Clin. Exp. Med. 2015, 8:1966-1975.
18. Kulstad J.J., Green P.S., Cook D.G., Watson G.S., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Rhoads K., Mehta P.D., Craft S. Differential modulation of plasma [beta]-amyloid by insulin in patients with Alzheimer disease. Neurology 2006, 66:1506-1510.
19. Macauley S.L., Stanley M., Caesar E.E., Yamada S.A., Raichle M.E., Perez R., Mahan T.E., Sutphen C.L., Holtzman D.M. Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo. J. Clin. Invest. 2015, 125:2463-2467.
20. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
21. Mayer C.J., Steinman L., Williams B., Topolski T.D., LoGerfo J. Developing a Telephone Assessment of Physical Activity (TAPA) questionnaire for older adults. Prev. Chronic Dis. 2008, 5:A24.
22. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997, 42:85-94.
23. Moran C., Beare R., Phan T.G., Bruce D.G., Callisaya M.L., Srikanth V. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 2015, 85:1123-1130. Alzheimer's Disease Neuroimaging, I.
24. Morris J.K., Vidoni E.D., Honea R.A., Burns J.M. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol. Aging 2014, 35:585-589. Alzheimer's Disease Neuroimaging, I.
25. Morris J.K., Honea R.A., Vidoni E.D., Swerdlow R.H., Burns J.M. Is Alzheimer's disease a systemic disease?. Biochim. Biophys. Acta 2014, 1842:1340-1349.
26. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
27. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes care 2007, 30:753-759.
28. Pathak D., Berthet A., Nakamura K. Energy failure: does it contribute to neurodegeneration?. Ann. Neurol. 2013, 74:506-516.
29. Picone P., Nuzzo D., Caruana L., Messina E., Barera A., Vasto S., Di Carlo M. Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF-kappaB activation: use of insulin to attenuate metformin's effect. Biochim. Biophys. Acta 2015, 1853:1046-1059.
30. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
31. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P., Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
32. Sakamoto S., Ishii K., Sasaki M., Hosaka K., Mori T., Matsui M., Hirono N., Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J. Neurol. Sci. 2002, 200:27-32.
33. Sato N., Morishita R. The roles of lipid and glucose metabolism in modulation of beta-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Front. Aging Neurosci. 2015, 7:199.
34. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20:S265-S279.
35. Tarczyluk M.A., Nagel D.A., Rhein Parri H., Tse E.H., Brown J.E., Coleman M.D., Hill E.J. Amyloid beta 1-42 induces hypometabolism in human stem cell-derived neuron and astrocyte networks. J. Cereb. Blood Flow Metab. 2015, 35:1348-1357.
36. Thambisetty M., Jeffrey Metter E., Yang A., Dolan H., Marano C., Zonderman A.B., Troncoso J.C., Zhou Y., Wong D.F., Ferrucci L., Egan J., Resnick S.M., O'Brien R.J. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013, 70:1167-1172.
37. Velayudhan L., Poppe M., Archer N., Proitsi P., Brown R.G., Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br. J. Psychiatry 2010, 196:36-40.
38. Willette A.A., Johnson S.C., Birdsill A.C., Sager M.A., Christian B., Baker L.D., Craft S., Oh J., Statz E., Hermann B.P., Jonaitis E.M., Koscik R.L., La Rue A., Asthana S., Bendlin B.B. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 2015, 11:504-510.e1.